Neuroscan (Exametazime)

Exametazime is a lipophilic compound that readily crosses the blood‑brain barrier. Once in the brain, its uptake is directly proportional to regional cerebral blood flow. The tracer emits gamma photons that are captured by a SPECT camera, producing images that reflect the distribution of blood flow throughout cerebral tissue.

The dose of Neuroscan is determined by the prescribing physician or nuclear medicine specialist based on the specific imaging protocol, patient weight, and the equipment used. Exact dosing information is individualized and should be obtained from the treating healthcare professional.

Safety data for exametazime in pregnancy and lactation are limited. The product should be used only when clearly needed, after a careful risk‑benefit assessment by the treating physician. If used, the potential radiation exposure to the fetus or infant should be considered, and breastfeeding may be paused as advised.

To order Neuroscan, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India supplies hospitals, pharmacies, and procurement teams worldwide. After verification of trade or institutional credentials, the sales team will respond with pricing, availability, shipping details (including cold‑chain logistics if required), and any necessary import documentation.

Neuroscan (exametazime) is a technetium‑99m‑based tracer similar to technetium‑99m HMPAO. Both provide high‑quality SPECT images of cerebral perfusion, but exametazime has slightly different lipophilicity, which may affect brain uptake kinetics. Choice of agent often depends on local availability, imaging protocol preferences, and regulatory approvals.

Neuroscan must be stored refrigerated at 2‑8 °C. Keep the vial in its original packaging, protect it from light, and avoid freezing or shaking. Before use, allow the product to reach room temperature if required by the imaging protocol, and handle it only in accordance with radiopharmacy safety standards.

Neuroscan is administered by intravenous injection performed by qualified medical personnel, typically in a nuclear medicine or radiology department. The injection is followed by a short uptake period, after which the patient is positioned for SPECT imaging to acquire cerebral perfusion data.

The most serious risks include severe allergic reactions such as anaphylaxis, marked hypotension, and cardiac arrhythmias. These events are rare but require immediate medical intervention. Patients should be monitored during and after injection, and any signs of distress should be reported to the healthcare team promptly.

Neuroscan should be avoided in individuals with known hypersensitivity to exametazime or any component of the formulation. It is also contraindicated in patients with severe renal impairment where excretion may be compromised, and in pregnant women unless the diagnostic benefit outweighs potential risks.